NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
Last trade$1.97
Day change+$0.145 (+7.97%)
Day range$1.79 – $2.08
Volume1,483,155
Market cap$196M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for NGEN.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for NGEN.
Recent news
Company coverage with links to the original publishers.
Newton Tech published a peer-reviewed study in Nature Medicine analyzing 3,328 adults, demonstrating that AI-powered movement analysis can predict health information across 18 body systems from video-based gait assessment. The technology identifies associations with 1,887 health measures including cardiovascular, metabolic, liver, and mental health indicators, offering pharmaceutical companies more sensitive clinical trial endpoints than traditional functional assessments.
NervGen Pharma Corp. announced the pricing of an underwritten public offering of 24 million common shares at US$2.50 per share, along with accompanying warrants at an exercise price of US$3.68, expected to raise approximately US$60 million in gross proceeds. The company plans to use the net proceeds to advance its lead therapeutic candidate NVG-291 through clinical studies. The offering is expected to close on May 26, 2026, with Leerink Partners and TD Cowen serving as joint bookrunning managers.
The spinal cord injury treatment market is experiencing significant expansion with multiple emerging therapies in development. Currently valued at USD 354 million in 2025, the market is projected to grow to USD 1.4 billion by 2034 at a 15.4% CAGR. Six key therapies are highlighted: KP-100IT (hepatocyte growth factor), Neuro-Cells (stem cell therapy), MT-3921 (RGMa inhibitor), Elezanumab (RGMa inhibitor), NFX88 (neuropathic pain relief), and NVG-291 (neurorepair peptide). These innovations address a critical unmet medical need, as STEMIRAC remains the only approved disease-modifying treatment, available exclusively in Japan.
NervGen Pharma announced the appointment of Adam Rogers, MD as President and Chief Executive Officer, effective immediately. Rogers, who previously served as Interim CEO and Chairman, led the company through its recent Nasdaq listing. The appointment reflects the Board's confidence in his execution of key milestones and his vision to advance NVG-291, the company's lead neuroreparative therapeutic candidate for spinal cord injury treatment.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.